Can Medication Side Effects Cause NSIP? What to Know
At a Glance
Certain medications can cause lung inflammation or scarring that resembles nonspecific interstitial pneumonia (NSIP), but the pattern does not prove the drug is responsible. Doctors compare medication timing, scans, symptoms, and tests for other causes; never stop treatment without supervision.
In this answer
4 sections
Yes, certain medications can cause lung inflammation and damage that creates an NSIP pattern on scans or biopsies [1][2]. This condition is generally known as drug-induced interstitial lung disease.
However, seeing an NSIP pattern does not automatically prove a medication caused it, as the same pattern can appear in autoimmune diseases or without any known cause [2]. Identifying a medication as the culprit offers an opportunity to halt further injury, but the process requires careful medical supervision to safely balance your breathing with the treatment of your other conditions.
How Clinicians Pinpoint the Cause
There is no single confirmatory test that proves a drug caused your lung injury [3]. Instead, your medical team must evaluate your full clinical picture and rule out other explanations. The extent of this testing is highly individualized:
- Reviewing Your Medication Timeline: Your doctor will compare the exact dates you started medications or changed dosages with the onset of your breathing symptoms [4][5]. The time it takes for drug-induced lung injury to develop varies widely depending on the drug; it can happen within days, take several months, or even appear after years of exposure [6].
- Checking for Known Culprits: While many drugs can cause lung issues, doctors look closely for medications known to carry higher risks of lung toxicity. These frequently include certain cancer therapies (like bleomycin, everolimus, or immune-checkpoint inhibitors), targeted therapies (like imatinib or nilotinib), and some heart medications (like amiodarone) [7][8][9].
- Ruling Out Alternatives: You may undergo blood tests, sputum testing, or sometimes a bronchoscopy (a procedure to look inside the lungs) to ensure an infection, an undetected autoimmune condition, a blood clot, or a heart problem isn’t the true cause [3][10]. Invasive testing is not automatically required for everyone.
- Imaging: Your team will review High-Resolution CT (HRCT) scans, which create highly detailed images of your lungs, to evaluate the specific pattern of lung injury [2][11].
What You Can Do Before Your Appointment
You can help your care team solve this puzzle by arriving prepared:
- Gather all of your prescription bottles, over-the-counter medicines, and supplements.
- Write down the exact dates you started each one, along with any recent dose changes.
- Note the approximate date you first noticed a cough or shortness of breath.
- Bring records of any home oxygen readings and prior lung scans.
Should You Stop Taking Your Medication?
Do not stop taking any prescribed medication abruptly without your doctor’s explicit instruction and supervision. Many medications linked to lung injury are essential treatments for serious conditions like cancer or severe heart disease.
- Supervised Withdrawal: If your clinician suspects a drug is causing your NSIP, they will carefully manage the process of stopping or replacing it [7]. If your symptoms or scans improve after the suspected drug is removed, it adds evidence to the diagnosis [5][11]. However, it does not absolutely prove it, as improvement could also result from other treatments or the natural course of the disease.
- Avoiding Rechallenge: Once a specific drug is identified as the likely cause, doctors generally advise against restarting it, as the lung injury can return much faster and more severely [8][12]. In very select situations where a medication is life-saving and the initial reaction was mild, specialists might carefully consider re-exposure. Never restart a suspected medication on your own.
Reversible Inflammation vs. Permanent Fibrosis
Your long-term prognosis after stopping the medication depends on the type and extent of the lung damage. Inflammation and scarring are not always an “either/or” situation; they often coexist.
- Inflammation: If your lung injury involves active inflammation (sometimes referred to as cellular NSIP), stopping the trigger medication often leads to significant improvement [7][1]. Your doctor might also prescribe a course of systemic corticosteroids (like prednisone) to calm the inflammation, though these are only used after careful evaluation because they carry risks, such as worsening hidden infections [7][4].
- Fibrosis: If the drug has caused established lung scarring (known as fibrosis), this damage is often difficult to reverse [13][14]. However, identifying and stopping the culprit drug can halt further damage, and some improvement in your breathing is still possible even if residual scarring limits a full recovery [15].
Because HRCT scans cannot perfectly separate active inflammation from permanent scarring on their own, your doctor will monitor your symptoms, oxygen needs, pulmonary-function tests, and repeat imaging over time to determine your overall progress.
When to Seek Urgent Medical Care
Drug-induced lung injury can sometimes cause rapid, severe drops in lung function. You should seek emergency medical evaluation immediately if you experience:
- Inability to speak in full sentences due to breathlessness [16]
- Bluish color in your lips or face [17]
- Confusion, fainting, or chest pain [4]
- Difficulty breathing even when you are resting [17][4]
- A drop in your oxygen levels that falls below your personalized action plan, or a new need for supplemental oxygen [17][18]
Ask your doctor for a specific oxygen saturation number that should prompt an emergency call.
Common questions in this guide
Can a medication really cause an NSIP pattern in the lungs?
How do doctors determine whether my medication caused NSIP?
Should I stop taking the medication suspected of causing NSIP?
Can drug-related NSIP improve after the medication is stopped?
Which medications are often linked to drug-induced lung injury?
When is medication-related lung injury an emergency?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Non-specific interstitial pneumonia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What evidence makes you think this is drug-induced rather than an autoimmune or idiopathic form of NSIP?
- 2.Looking at my full clinical picture—symptoms, breathing tests, and scans—do you see signs of active inflammation that might improve if we stop the medication?
- 3.If you suspect my medication caused this, what is the safest way to transition off of it without jeopardizing the treatment of my underlying condition?
- 4.Are there alternative medications we can use that do not carry the same risk of lung toxicity?
- 5.How soon after stopping the suspected medication should we repeat my lung function tests or scans to monitor my progress?
References
References (18)
- 1
Bispecific T-Cell Engagers-Induced Interstitial Lung Disease: Two Case Reports Confirmed by Transbronchial Lung Cryobiopsy.
Morviducci M, Maraz F, Ravaglia C, et al.
Respiration; international review of thoracic diseases 2025; (104(11)):880-886 doi:10.1159/000547111.
PMID: 40570828 - 2
The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review.
Dinkel J, Kneidinger N, Tarantino P
Insights into imaging 2024; (15(1)):191 doi:10.1186/s13244-024-01771-z.
PMID: 39090512 - 3
Idiopathic non-specific interstitial pneumonia.
Belloli EA, Beckford R, Hadley R, Flaherty KR
Respirology (Carlton, Vic.) 2016; (21(2)):259-68 doi:10.1111/resp.12674.
PMID: 26564810 - 4
Drug-induced interstitial lung disease.
Spagnolo P, Bonniaud P, Rossi G, et al.
The European respiratory journal 2022; (60(4)) doi:10.1183/13993003.02776-2021.
PMID: 35332071 - 5
[Drug-induced interstitial lung diseases].
Bonniaud P, Georges M, Favrolt N, Camus P
La Revue du praticien 2014; (64(7)):951-6.
PMID: 25362778 - 6
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.
Terbuch A, Tiu C, Candilejo IM, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(18)):4805-4813 doi:10.1158/1078-0432.CCR-20-0454.
PMID: 32332017 - 7
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.
Conte P, Ascierto PA, Patelli G, et al.
ESMO open 2022; (7(2)):100404 doi:10.1016/j.esmoop.2022.100404.
PMID: 35219244 - 8
A case report of nilotinib-induced irreversible interstitial lung disease.
Cho JY, Lee OJ, Kwon J, et al.
Medicine 2022; (101(4)):e28701 doi:10.1097/MD.0000000000028701.
PMID: 35089229 - 9
Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database.
Matsumoto K, Nakao S, Hasegawa S, et al.
SAGE open medicine 2020; (8()):2050312120918264 doi:10.1177/2050312120918264.
PMID: 32528682 - 10
Drug-induced lung disease: a narrative review.
Bridi GDP, Fonseca EKUN, Kairalla RA, et al.
Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 2024; (50(4)):e20240110 doi:10.36416/1806-3756/e20240110.
PMID: 39356911 - 11
Imatinib-Associated Interstitial Lung Disease with a Fibrotic NSIP Pattern on Transbronchial Lung Cryobiopsy: A Case Report and Review of the Literature.
Mari PV, Carriera L, Lococo F, et al.
Reports (MDPI) 2026; (9(3)) doi:10.3390/reports9030303.
PMID: 42784028 - 12
Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
Kashizaki F, Tanaka A, Sekido Y
Journal of medical case reports 2022; (16(1)):316 doi:10.1186/s13256-022-03556-8.
PMID: 35999557 - 13
Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype.
Ravaglia C, Nicholson AG
Current opinion in pulmonary medicine 2021; (27(5)):355-362 doi:10.1097/MCP.0000000000000810.
PMID: 34397611 - 14
Imaging of Pulmonary Fibrosis: An Update, From the AJR Special Series on Imaging of Fibrosis.
Lee KS, Han J, Wada N, et al.
AJR. American journal of roentgenology 2024; (222(2)):e2329119 doi:10.2214/AJR.23.29119.
PMID: 37095673 - 15
Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030).
Okuda R, Ogura T, Hisata S, et al.
Respiratory investigation 2025; (63(3)):365-372 doi:10.1016/j.resinv.2025.02.009.
PMID: 40101437 - 16
Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
Johkoh T, Lee KS, Nishino M, et al.
Chest 2021; (159(3)):1107-1125 doi:10.1016/j.chest.2020.11.027.
PMID: 33450293 - 17
Mesalazine-associated lung fibrosis: case report and literature review.
Uslu NZ, Adleh MH, Bilir E, et al.
Respiratory medicine case reports 2025; (58()):102284 doi:10.1016/j.rmcr.2025.102284.
PMID: 41030323 - 18
Pulmonary Tumor Embolism Microangiopathy: A Cause of Respiratory Failure in Advanced Malignancy.
Anwar K, Hanafi M, Mishall B, et al.
South Dakota medicine : the journal of the South Dakota State Medical Association 2021; (74(10)):463-466.
PMID: 34995427
This page is for informational purposes only and does not constitute medical advice. Do not stop or restart a prescribed medication without your clinician’s guidance, especially if you have breathing symptoms.